VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
AGMB-447
Phase 1
Small molecule
A
Agomab Spain S.L.
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
IPF
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
IPF
Phase 1
Completed
Clinical
Trials by Indication
[1]
IPF
1 trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of Inhaled AGMB-447 in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
Completed
·
A
Agomab Spain S.L.
·
Phase 1
·
NCT06181370
·
143 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for AGMB-447. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
AGMB-447 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for AGMB-447. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Agomab Spain S.L. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 1
[1]
Company
A
Agomab Spain S.L.
Related News